Lv3
330 积分 2025-09-13 加入
比咖啡更提神的是打翻咖啡。
Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non–Small Cell Lung Cancer
7天前
已完结
Optimizing KRAS Therapeutics for Non–Small Cell Lung Cancer
28天前
已完结
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
2个月前
已完结
635P Cross-over adjusted overall survival for amivantamab plus chemotherapy vs chemotherapy in first-line EGFR exon-20 insertion NSCLC
2个月前
已关闭
EGFR exon 20 insertions mutation in lung adenocarcinoma and its response by high-dose of Furmonertinib: a real-world study
2个月前
已关闭
4O: Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study
3个月前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
3个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
3个月前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
4个月前
已完结
A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer
4个月前
已关闭
皖公网安备34019202002308
